BNP Paribas Financial Markets increased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 252.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 148,942 shares of the company's stock after purchasing an additional 106,652 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.18% of CRISPR Therapeutics worth $10,152,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. ARK Investment Management LLC lifted its stake in CRISPR Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company's stock valued at $534,360,000 after buying an additional 1,372,986 shares during the last quarter. Capital International Investors lifted its stake in CRISPR Therapeutics by 0.8% in the fourth quarter. Capital International Investors now owns 6,134,450 shares of the company's stock valued at $384,017,000 after buying an additional 48,938 shares during the last quarter. Vanguard Group Inc. lifted its stake in CRISPR Therapeutics by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 1,590,651 shares of the company's stock valued at $99,575,000 after buying an additional 51,926 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in CRISPR Therapeutics by 2.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 653,023 shares of the company's stock valued at $40,879,000 after buying an additional 15,085 shares during the last quarter. Finally, Norges Bank purchased a new stake in CRISPR Therapeutics in the fourth quarter valued at approximately $38,661,000. Hedge funds and other institutional investors own 69.20% of the company's stock.
Insider Activity at CRISPR Therapeutics
In related news, CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the sale, the chief executive officer now owns 208,122 shares of the company's stock, valued at $12,468,589.02. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, COO Julianne Bruno sold 3,366 shares of the stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at $378,327.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares in the company, valued at $12,468,589.02. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts have recently commented on CRSP shares. Citigroup cut their price target on CRISPR Therapeutics from $89.00 to $84.00 and set a "buy" rating for the company in a research note on Thursday, May 23rd. Oppenheimer cut their price target on CRISPR Therapeutics from $102.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday, May 10th. Piper Sandler restated an "overweight" rating and set a $105.00 price target on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Cantor Fitzgerald restated a "neutral" rating on shares of CRISPR Therapeutics in a research note on Thursday, May 9th. Finally, Needham & Company LLC restated a "buy" rating and set a $88.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, June 27th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $75.71.
Read Our Latest Analysis on CRISPR Therapeutics
CRISPR Therapeutics Price Performance
CRISPR Therapeutics stock opened at $55.03 on Wednesday. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The stock's fifty day moving average is $56.58 and its two-hundred day moving average is $64.09.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.08). The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $25.53 million. The firm's revenue was down 99.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.67) earnings per share. Research analysts anticipate that CRISPR Therapeutics AG will post -5.51 earnings per share for the current fiscal year.
About CRISPR Therapeutics
(Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Featured Articles
- Five stocks we like better than CRISPR Therapeutics
- Stock Market Upgrades: What Are They?
- Top 2 Cybersecurity Stocks Booming in an Age of Rising Threats
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
- What is a Bond Market Holiday? How to Invest and Trade
- Uncover Why This Pharma Stock Jumped 400% on Study Update
→ $2.05 Bitcoin Dividend on July 29 (Without Owning Bitcoin) (From Investors Alley) (Ad)
Should you invest $1,000 in CRISPR Therapeutics right now?
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Ten Starter Stocks For Beginners to Buy Now
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
